Biofrontera Inc. Common Stock
BFRIBiofrontera Inc. is a biopharmaceutical company focused on developing and commercializing innovative products for dermatological conditions. It primarily markets its leading prescription product, Ameluz, for actinic keratosis, and develops treatments leveraging its proprietary photodynamic therapy technology. The company aims to address unmet medical needs in dermatology through research, development, and commercialization efforts.
Company News
Biofrontera completed its Phase 1 pharmacokinetic study for Ameluz® to expand treatment of actinic keratoses to neck, trunk, and extremities, with plans to submit a supplemental New Drug Application to the FDA in summer 2026.
Biofrontera reported a 15% revenue increase in Q2 2025, with record Ameluz sales and strategic shifts towards a royalty model. The company is advancing clinical trials for label expansions in actinic keratosis and basal cell carcinoma treatments.
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 54.55% and 88.87%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates. Jabil posted adjusted earnings of $1.68 per share, beating estimates of $1.66 per share. The company’s quarterly sales came in at $6.77 billion, missing expectations of $6...
Penny stocks to watch with relative strength in the stock market today. The post Best Penny Stocks To Watch After Powell’s Jackson Hole Speech appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
